Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
June 18, 2020
Primary Completion Date
July 27, 2023
Study Completion Date
July 27, 2023
Conditions
Recurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG
Alisertib
Given PO
DRUG
Osimertinib
Given PO
DRUG
Sapanisertib
Given PO
Trial Locations (1)
77030
M D Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT04479306 - Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter